HIV DNA vaccine - Merck & Co.

Drug Profile

HIV DNA vaccine - Merck & Co.

Alternative Names: Human Immunodeficiency Virus DNA vaccine - Merck & Co.

Latest Information Update: 29 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Vical
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 20 Mar 2002 A study has been added to the adverse events and Viral Infections immunogenicity sections
  • 11 Mar 2002 A study has been added to the Viral Infections pharmacodynamics section
  • 27 Dec 2001 The National Institute of Allergy and Infectious Disease has entered into an agreement with Merck & Co to evaluate candidate vaccines developed by the company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top